At a Glance
| Property | Detail |
|---|---|
| What it is | A synthetic 15-amino-acid peptide derived from a protein in gastric juice (“body protection compound”) |
| Evidence Level | Limited — no human dose-finding trials; all dosing extrapolated from animal models. Three uncontrolled human studies, 30 people in total (Poolton et al., 2026) |
| Typical Dose (SC) | 250-500 mcg, 1-2x daily |
| Typical Dose (Oral) | 500-1,000 mcg, once or twice daily on an empty stomach |
| Cycle Length | 4-6 weeks on, 2-4 weeks off |
| Primary Routes | Subcutaneous injection, oral |
| Regulatory Status | Not approved for any human use by the FDA, EMA or BfArM; on FDA’s list of compounding substances with safety concerns |
| Anti-doping (WADA 2026) | Prohibited at all times; named explicitly under S0 (non-approved substances) |
Protocol Table: Dose, Route, Timing and Basis
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
One row per use case. The Basis column says where each number comes from: a published human study (Trial, with PMID), a protocol reported by at least two independent compilations (Practice protocol), or community reports only (Anecdotal).
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Tendon, ligament or muscle injury, standard | 250-500 mcg | SC, near the injury or abdominal | Once or twice daily | 4-8 weeks | Practice protocol (Peptide Protocol Wiki; Peptide DB) |
| More serious injury, front-loaded | 500 mcg (Peptide DB lists up to 1,000 mcg) | SC, near the injury | Twice daily, morning and evening | 4-6 weeks | Practice protocol (Peptide Protocol Wiki; Peptide DB) |
| Gut symptoms (gastritis, IBS-type complaints) | 500-1,000 mcg | Oral, empty stomach | Once or twice daily | 4-8 weeks | Anecdotal (listed as a common community protocol by Peptide Protocol Wiki; no human oral data) |
| Low-dose maintenance | 100-250 mcg | SC | Once daily | 4 weeks on, 2 weeks off, repeated | Anecdotal (Peptide Protocol Wiki; Peptide DB) |
| Combined with TB-500 (“Wolverine” stack) | BPC-157 250-500 mcg daily + TB-500 2-2.5 mg twice weekly | SC | BPC-157 daily, TB-500 twice weekly | 4-8 weeks | Practice protocol (Peptide DB stack page; Peptide Protocol Wiki) |
| Interstitial cystitis, single procedure | 10 mg in total, injected around the inflamed bladder wall during cystoscopy | Intravesical injection | Once | Single procedure | Trial (uncontrolled pilot, 12 women; PMID 39325560) |
| Intravenous safety check | 10 mg on day 1, 20 mg on day 2, each in 250 mL saline over one hour | IV | Two consecutive days | 2 days | Trial (safety pilot, 2 adults; PMID 40131143) |
The two Trial rows are the only published human doses with a stated amount, and neither was a dose-finding study. A systematic review found three human studies with 30 participants in total, all judged to be of poor methodological quality (Poolton 2026). Everything in the practice rows comes from scaling animal doses and from what users report over time.
Technique, reconstitution and storage are in the peptide injection guide.
How Much BPC-157 Should You Actually Take?
This is the question I get most often about BPC-157 peptide therapy, and I want to be direct about the answer before we go deeper: nobody knows with certainty. There are no published human dose-finding studies for BPC-157. Every dosing protocol you encounter — including the ones used in clinical practice — is extrapolated from animal data using allometric scaling, combined with years of clinical observation.
That does not mean we are guessing blindly. It means we are working with the best available evidence, and I want you to understand exactly where that evidence comes from and where the gaps are.
The most commonly used range for subcutaneous BPC-157 is 250-500 mcg administered once or twice daily. For oral administration targeting gastrointestinal conditions, 500-1,000 mcg once or twice daily on an empty stomach is the typical community protocol. These are not magic numbers — they represent the range where clinical response appears most consistent with the fewest reported side effects.
What BPC-157 Is and What It Does
BPC-157 is a pentadecapeptide (15 amino acids) based on a sequence from a larger protein found in human gastric juice. Most of the research comes from one group in Zagreb, which has published on it since the early 1990s. In rats, BPC-157 protected the stomach and gut lining against a wide range of injuries (Sikiric et al., 2011) and has been studied along the brain-gut axis (Sikiric et al., 2016).
The proposed mechanisms, all from animal and cell studies, include:
- Blood-vessel growth (angiogenesis): BPC-157 increased VEGFR2 signalling and new vessel formation in rat and cell models (Hsieh et al., 2017; Seiwerth et al., 2018).
- Tendon cell behaviour: in tendon fibroblast cultures it promoted outgrowth, survival and migration (Chang et al., 2011).
- Tendon-to-bone healing in rats: after surgical Achilles detachment, treated rats healed faster (Krivic et al., 2006).
These are interesting results. They are also results in rats, mostly from a single laboratory, and they have not been reproduced in controlled human trials.
What the Evidence Shows
Preclinical
The animal literature is large and mostly positive: gut lesions, tendon and ligament injuries, muscle damage, and vascular models. Two cautions apply. Most studies come from the same research group, and almost all use rat models whose dosing, routes and healing timelines do not translate directly to people (McGuire et al., 2025).
Human
A PROSPERO-registered systematic review searched the literature up to June 2026 and found three human studies (Poolton et al., 2026):
| Study | Design | n | What was studied | Finding | Certainty |
|---|---|---|---|---|---|
| Lee & Padgett, 2021 | Retrospective, no control group | 16 | Intra-articular injection for knee pain (4 of 16 also had thymosin beta-4) | 14 of 16 reported less pain at phone follow-up | Very low |
| Lee et al., 2024 | Retrospective pilot, no control group | 12 | 10 mg in total injected into the bladder wall during cystoscopy, for interstitial cystitis | 10 of 12 reported complete symptom resolution | Very low |
| Lee et al., 2025 | Prospective safety pilot | 2 | Intravenous infusion on two consecutive days | No change in the blood tests measured, no reported side effects | Very low |
The reviewers judged all three studies to be of poor methodological quality, rated the overall certainty of evidence as very low, and concluded that BPC-157 “should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials”. None of these studies had a placebo group, none measured healing objectively, and two participants cannot tell us anything about rare side effects. That is the context for every dose below.
How Animal Doses Translate to Human Doses
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
The foundational BPC-157 research from Professor Sikiric’s laboratory at the University of Zagreb used doses in the range of 10 mcg/kg body weight in rats, administered intraperitoneally or subcutaneously. Some studies used doses as low as 1 mcg/kg and as high as 50 mcg/kg.
Allometric scaling — the process of converting an effective animal dose to a human-equivalent dose — is not as simple as multiplying by body weight. The FDA guidance document on estimating initial safe starting doses recommends using body surface area conversion factors (Nair & Jacob, 2016). For rat-to-human conversion, the standard factor is approximately 6.2, meaning you divide the rat dose (in mg/kg) by 6.2 to estimate the human equivalent dose in mg/kg.
Using this approach with the most commonly effective rat dose of 10 mcg/kg:
| Parameter | Calculation |
|---|---|
| Rat effective dose | 10 mcg/kg |
| Human equivalent (÷ 6.2) | ~1.6 mcg/kg |
| 70 kg human | ~112 mcg |
| 80 kg human | ~128 mcg |
| 90 kg human | ~145 mcg |
This gives you a human equivalent dose of roughly 100-150 mcg for a single administration. In practice, most clinicians use 250-500 mcg — approximately 2-4 times the strict allometric conversion. The rationale for this upward adjustment includes the difference between intraperitoneal administration in rats (which delivers the peptide directly to the peritoneal cavity with high local bioavailability) and subcutaneous injection in humans (which requires the peptide to be absorbed and distributed systemically before reaching the target tissue).
This is an honest assessment of the dosing rationale. It is educated estimation, not precise pharmacokinetics. Body-surface-area conversion was designed to choose a safe starting dose for a first-in-human trial, not to predict an effective dose.
Subcutaneous Injection Protocol
Subcutaneous injection is the most common route of administration for musculoskeletal applications. The peptide is injected into the fatty tissue beneath the skin, ideally as close to the injury site as practical.
Standard Protocol
| Parameter | Recommendation |
|---|---|
| Dose | 250-500 mcg per injection |
| Frequency | Once or twice daily |
| Injection site | Subcutaneous, near the injury when possible |
| Timing | Morning and/or evening, consistent timing |
| Cycle length | 4-8 weeks |
| Rest period | 2-4 weeks between cycles |
Injection Site Selection
For localized injuries — a torn rotator cuff, Achilles tendinopathy, lateral epicondylitis — injecting subcutaneously as close to the injury as anatomically reasonable is the standard approach. The hypothesis is that local injection creates a higher local concentration of the peptide at the target tissue. Whether this meaningfully increases efficacy compared to injection at a distant site has not been formally studied in humans.
For systemic applications or conditions that are not anatomically localized (such as general recovery or neuroprotection), injection into the abdominal subcutaneous fat is the most common approach. The abdomen offers consistent absorption and is technically simple for self-administration.
The Starting Approach Most Often Discussed
When I coach patients through this decision (mostly in the US), the approach we usually discuss is to start at 250 mcg once daily for the first week. If tolerated well and the clinical response is insufficient, the dose is typically increased to 250 mcg twice daily or 500 mcg once daily. Starting at the lower end of the range allows tolerance to be assessed before escalating. Practitioners commonly report that the difference between once and twice daily dosing is most apparent in acute injury recovery — where the additional dose seems to maintain tissue levels more consistently — and less important for chronic conditions.
Oral Dosing Protocol
BPC-157 is unusual among peptides in that it is stable in gastric juice. This acid stability is related to its high proline content and its biological origin as a fragment of a gastric protein. This stability makes oral administration a viable route, particularly for gastrointestinal targets.
Standard Oral Protocol
| Parameter | Recommendation |
|---|---|
| Dose | 500-1,000 mcg per dose |
| Frequency | Once or twice daily |
| Timing | On an empty stomach, 30 minutes before food |
| Cycle length | 4-8 weeks |
| Rest period | 2-4 weeks between cycles |
Why Higher Oral Doses?
The oral dose is typically higher than the subcutaneous dose because oral bioavailability is inherently lower. Even though BPC-157 survives the acidic gastric environment, it still must cross the intestinal epithelium to enter systemic circulation. First-pass metabolism in the liver further reduces the amount of peptide that reaches non-GI target tissues.
For gastrointestinal targets specifically — inflammatory bowel disease, NSAID-induced gastropathy, leaky gut — oral administration may actually be preferable because the peptide makes direct contact with the GI mucosa before systemic absorption. This is the one scenario where oral delivery may have an advantage over injection.
Oral vs. Subcutaneous: When to Use Which
| Target | Preferred Route | Rationale |
|---|---|---|
| Tendon/ligament injury | Subcutaneous (near site) | Higher local tissue concentration |
| Muscle tear | Subcutaneous (near site) | Direct tissue access |
| Joint inflammation | Subcutaneous (near joint) | Local delivery preferred |
| Gastric ulcer / gastropathy | Oral | Direct mucosal contact |
| Inflammatory bowel disease | Oral | Direct intestinal delivery |
| Leaky gut / intestinal permeability | Oral | Direct epithelial contact |
| General recovery / systemic | Either | SC may have better bioavailability |
| Neuroprotection | Subcutaneous (abdominal) | Systemic delivery needed |
Loading and Maintenance Protocols
Some practitioners use a loading-phase approach, starting with a higher dose or frequency for the first 1-2 weeks before transitioning to a maintenance dose. The rationale is to establish tissue levels more quickly during the acute phase of healing.
Example Loading Protocol
| Phase | Duration | Dose | Frequency |
|---|---|---|---|
| Loading | Weeks 1-2 | 500 mcg SC | Twice daily |
| Maintenance | Weeks 3-6 | 250 mcg SC | Once daily |
| Rest | Weeks 7-10 | None | — |
I want to be transparent: the loading protocol is not based on pharmacokinetic data. It is based on the clinical logic that tissue repair processes are most active in the first 1-2 weeks following injury, and higher peptide availability during this window may be beneficial. Some clinicians report better outcomes with loading phases. Others use a flat-dose protocol throughout and report equivalent results. Without comparative studies, this remains a matter of clinical judgment. For more serious injuries, Peptide DB lists up to 1,000 mcg twice daily. That upper figure comes from a single compilation, so the protocol table gives 500 mcg twice daily as the practice dose and notes 1,000 mcg separately.
Body Weight Considerations
BPC-157 dosing is generally not adjusted for body weight in clinical practice, despite the fact that the allometric scaling from animal data is weight-based. The reason is pragmatic: the available evidence does not suggest a meaningful difference in response across the 200-500 mcg range for adults of varying body weights, and the therapeutic window appears wide enough that weight-based adjustments add complexity without clear benefit.
That said, for people at the extremes of body weight:
| Body Weight | Suggested Starting Dose |
|---|---|
| Under 60 kg | 200-250 mcg SC |
| 60-90 kg | 250-500 mcg SC |
| Over 90 kg | 500 mcg SC |
These are conservative starting points. The nuance matters here — there is no evidence that a 100 kg person needs exactly twice the dose of a 50 kg person.
Cycling: Why and How
Most practitioners recommend cycling BPC-157 rather than continuous use. The typical pattern is 4-8 weeks on followed by 2-4 weeks off (Practice protocol; see the table above). The rationale for cycling includes:
-
Receptor sensitivity. Chronic exposure to any signaling peptide can theoretically lead to receptor downregulation. Cycling may preserve receptor sensitivity, though this has not been demonstrated specifically for BPC-157.
-
Healing timelines. Most acute musculoskeletal injuries show the majority of their tissue-level healing response within 4-6 weeks. Extended use beyond this window may offer diminishing returns.
-
Safety conservatism. Given the absence of long-term human safety data, limiting continuous exposure is a reasonable precautionary measure.
For chronic conditions such as inflammatory bowel disease, longer cycles of 6-8 weeks may be appropriate, with clinical reassessment between cycles to determine whether continued treatment is warranted.
Combination Protocols
BPC-157 is frequently combined with other peptides, most commonly TB-500 tissue repair peptide (Thymosin Beta-4 fragment). The rationale is that BPC-157 and TB-500 operate through partially distinct mechanisms — BPC-157 primarily through angiogenesis and growth factor modulation, TB-500 primarily through actin regulation and cell migration — and may have complementary effects on tissue repair. The only human data on the combination is the uncontrolled knee-injection series of 16 patients described above (Lee & Padgett, 2021).
A common combination protocol:
| Peptide | Dose | Frequency | Notes |
|---|---|---|---|
| BPC-157 | 250-500 mcg SC | Once daily | Near injury site |
| TB-500 | 2-2.5 mg SC | 2x per week | Any SC site |
For a detailed comparison of these two peptides, see BPC-157 vs TB-500: Which Peptide for Tissue Repair?.
Reconstitution and Storage
BPC-157 is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water before injection.
Reconstitution Steps
- Add bacteriostatic water slowly to the vial — do not shake, swirl gently
- Common reconstitution: 2 mL bacteriostatic water to a 5 mg vial = 2,500 mcg/mL
- This means 0.1 mL (10 units on an insulin syringe) = 250 mcg
- Store reconstituted peptide refrigerated (2-8°C)
- Use within 4 weeks of reconstitution
Concentration Table
| Vial Size | Water Added | Concentration | 250 mcg = | 500 mcg = |
|---|---|---|---|---|
| 5 mg | 1 mL | 5,000 mcg/mL | 0.05 mL (5 units) | 0.10 mL (10 units) |
| 5 mg | 2 mL | 2,500 mcg/mL | 0.10 mL (10 units) | 0.20 mL (20 units) |
What the Evidence Does Not Tell Us
Here is what the evidence shows: BPC-157 has consistent, reproducible effects across hundreds of animal studies at the doses described above. Here is what the evidence does not tell us:
- The optimal human dose for any specific indication
- Whether twice daily dosing is meaningfully better than once daily
- Whether local injection is superior to distal injection for localized injuries
- The ideal cycle length or rest period
- Whether body weight meaningfully affects the required dose
- Long-term safety at any dose
This is not unusual for a peptide at this stage of clinical development. But it is important that you understand the difference between a well-characterized pharmacological profile and a protocol built on extrapolation and clinical observation. The protocols in this article represent the latter.
Known and Theoretical Risks
Unknown long-term safety. No human study has followed people for longer than a few weeks. Absence of reported harm in 30 people is not evidence of safety.
Blood-vessel growth. BPC-157’s best-documented animal effect is pro-angiogenic (Hsieh et al., 2017). Angiogenesis helps wounds heal, and tumours also depend on it to grow. Nobody has shown that BPC-157 promotes cancer. Nobody has studied it in people with a current or past tumour either, so the question is open.
What is actually in the vial. BPC-157 sold online is a “research chemical” with no pharmaceutical quality control. When researchers test-bought another injectable peptide (semaglutide) from unregulated online sellers, the content was a fraction of the labelled amount and every sample contained endotoxin (Ashraf et al., 2024). The FDA specifically lists immunogenicity and peptide-related impurities as concerns for compounded BPC-157.
Injection-related harm. Injecting non-sterile or poorly made products risks local infection, abscesses and, rarely, bloodstream infection. Injecting near an injured tendon adds the risk of masking a problem that needs proper diagnosis.
Delayed diagnosis. A tendon rupture, a stress fracture or inflammatory bowel disease treated “with a peptide” instead of investigated is a real harm, even if the peptide itself does nothing.
For a fuller discussion, see BPC-157 Side Effects: What the Evidence Actually Shows.
Regulatory Status
- United States (FDA): not an approved drug. BPC-157 appears on the FDA page Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026), among substances formerly in category 2 whose compounding nominations were withdrawn. FDA’s stated concerns: possible immunogenicity, complexities with peptide-related impurities, and “no, or only limited, safety-related information” for the proposed routes. BPC-157 is not on the 503A bulks list and is not in category 1 (“under evaluation”) of FDA’s May 2026 list.
- EU and Germany: not authorised as a medicine by the European Medicines Agency or Germany’s BfArM. “Research use only” is a disclaimer, not a quality standard: such products are neither approved nor tested for human use.
- Sport (WADA 2026 Prohibited List): prohibited at all times. BPC-157 is named explicitly as an example under S0, non-approved substances. Athletes subject to testing can face sanctions regardless of the reason for use.
When to Talk to a Physician
If you are considering BPC-157, the injury or condition behind that decision deserves a diagnosis first. For tendon and joint problems, that usually means a clinical examination and, where needed, ultrasound or MRI. For gut symptoms, it means ruling out conditions such as inflammatory bowel disease, coeliac disease or ulcers, which have effective, tested treatments.
Seek medical care promptly for a sudden “snap” or loss of strength in a tendon, a hot swollen joint, fever, blood in the stool, or unintended weight loss. If you have already used BPC-157, tell your doctor what you used, the source, the route and the duration, and report any redness, swelling or pain at injection sites.
Registered clinical trials remain the most controlled setting for access. Search ClinicalTrials.gov or the EU Clinical Trials Register.
The Bottom Line
BPC-157 dosing at 250-500 mcg subcutaneously once or twice daily for 4-8 week cycles is the most commonly used protocol, supported by allometric scaling from animal data and consistent clinical observation. Oral dosing at 500-1,000 mcg once or twice daily is the usual community protocol for gastrointestinal targets. All dosing remains extrapolated — not validated by human dose-finding trials — and the human evidence base is 30 people in three uncontrolled studies. Work with a qualified physician, start conservatively, and adjust based on response.
For the full overview of BPC-157 mechanisms and evidence, see BPC-157: What the Research Actually Shows.
References
- Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026. PMID: 42885452.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PMID: 21548867.
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016. PMID: 27138887.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PMID: 27847966.
- Seiwerth S, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018. PMID: 29998800.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID: 21030672.
- Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. PMID: 16583442.
- McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025. PMID: 40789979.
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PMID: 34324435.
- Lee E, et al. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PMID: 39325560.
- Lee E, et al. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PMID: 40131143.
- Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31. PMID: 27057123.
- Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024. PMID: 39509151.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026); Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated 14 May 2026).
- World Anti-Doping Agency. The 2026 Prohibited List, valid 1 January 2026 (S0).
Disclaimer: This article is for informational purposes only and reflects current published research and clinical observation. The doses described summarise what is used in research and practice; they are not a prescription or individual medical advice. BPC-157 is not approved for human use by the FDA, EMA or BfArM. Consult a qualified physician before pursuing any peptide therapy.